Skip to main content
. 2023 Nov 14;29(1):27–35. doi: 10.1007/s10147-023-02422-x

Fig. 1.

Fig. 1

Swimmer plot indicating clinical outcomes for patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with trastuzumab deruxtecan. Dosage of trastuzumab deruxtecan over time is indicated by colored bars; symbols indicate clinical outcomes. The case numbers do not reflect the order in which the cases were reported. GEJ gastroesophageal junction; HER2 human epidermal growth factor receptor 2; RECIST response evaluation criteria in solid tumors